BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 855 filers reported holding BAXTER INTL INC in Q3 2013. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $6,702,000 | -45.0% | 148,200 | -50.0% | 0.04% | -38.7% |
| Q1 2016 | $12,186,000 | -50.8% | 296,648 | -54.3% | 0.06% | -54.1% |
| Q4 2015 | $24,756,000 | -56.6% | 648,922 | -62.6% | 0.14% | -31.8% |
| Q3 2015 | $57,069,000 | +316.6% | 1,737,259 | +829.5% | 0.20% | +435.1% |
| Q4 2014 | $13,698,000 | -2.9% | 186,900 | -4.9% | 0.04% | -9.8% |
| Q3 2014 | $14,103,000 | -1.4% | 196,500 | -0.7% | 0.04% | -4.7% |
| Q2 2014 | $14,301,000 | -3.8% | 197,800 | -2.1% | 0.04% | -12.2% |
| Q1 2014 | $14,860,000 | -65.8% | 201,953 | -67.7% | 0.05% | -56.2% |
| Q4 2013 | $43,493,000 | -13.1% | 625,349 | -17.9% | 0.11% | -21.1% |
| Q3 2013 | $50,043,000 | -6.0% | 761,800 | -0.8% | 0.14% | -15.0% |
| Q2 2013 | $53,213,000 | – | 768,200 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |